ArticleNature nanotechnology2020
Phage capsid nanoparticles with defined ligand arrangement block influenza virus entry.
Abstract read
In one paragraph
Article in Nature nanotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Virus-Mediated Self-Assembly of Functional Cyclodextrins for Antiviral Inhibition.Angewandte Chemie (International ed. in English) · 2026Article
- Supramolecules for Pathogen Inhibition: From Polymers to Self-Assembled Nanosystems.Accounts of materials research · 2026Article
- Supramolecular Carbohydrate Assemblies with Tunable Glycan Surfaces.Angewandte Chemie (International ed. in English) · 2026Article
- Synthesis and Application of Glycopolymers Having Sialoglycosides.Advances in experimental medicine and biology · 2026Review
- From neuraminidase inhibitors to novel mechanisms: expanding therapeutic strategies against influenza.Frontiers in cellular and infection microbiology · 2026Review
- Self-assembled nanosheets of biocompatible polymers as universal cell-membrane mimic to block viral infection.Bioactive materials · 2025Article
- Gold Nanoparticles with Adaptable Self-Assembled Monolayer Shells Allow Multivalent Inhibition and Sensing of Influenza Virus at Ultralow Concentrations.ACS central science · 2025Article
- Label-Free and Microplate-Based Dissection of Glycan-Virus Interactions Using Polymer-Tethered Glyconanoparticles.Small methods · 2025Article
- CD44-targeted virus-mimicking nanomedicine eliminates cancer stem cells and mitigates chemoresistance in head and neck squamous cell carcinoma.Materials today. Bio · 2025Article
- A Comprehensive Review on Phage Therapy and Phage-Based Drug Development.Antibiotics (Basel, Switzerland) · 2024Review
- Self-Assembly of Polymers and Their Applications in the Fields of Biomedicine and Materials.Polymers · 2024Review
- Pathogen-binding nanoparticles to inhibit host cell infection by heparan sulfate and sialic acid dependent viruses and protozoan parasites.Smart medicine · 2024Review
- Tapered chiral nanoparticles as broad-spectrum thermally stable antivirals for SARS-CoV-2 variants.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Nanotechnology-based theranostic and prophylactic approaches against SARS-CoV-2.Immunologic research · 2024Review
- Cryo-electron microscopy in the study of virus entry and infection.Frontiers in molecular biosciences · 2024Review
- Viral Attachment Blocking Chimera Composed of DNA Origami and Nanobody Inhibits Pseudorabies Virus Infection In Vitro.ACS nano · 2023Article
- Emerging drug design strategies in anti-influenza drug discovery.Acta pharmaceutica Sinica. B · 2023Review
- Net-Shaped DNA Nanostructures Designed for Rapid/Sensitive Detection and Potential Inhibition of the SARS-CoV-2 Virus.Journal of the American Chemical Society · 2023Article
- Nanotubes from bacteriophage tail sheath proteins: internalisation by cancer cells and macrophages.Nanoscale advances · 2023Article
- Nanomedicines: intervention in inflammatory pathways of cancer.Inflammopharmacology · 2023Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Daniel Lauster *Institut für Chemie und Biochemie, Organische Chemie, Freie Universität Berlin, Berlin, Germany.
Simon Klenk *Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Kai LudwigForschungszentrum für Elektronenmikroskopie und Gerätezentrum BioSupraMol, Institut für Chemie und Biochemie, Freie Universität Berlin, Berlin, Germany.
Saba NojoumiInstitut für Chemie, Biokatalyse, Technische Universität Berlin, Berlin, Germany.
Sandra BehrenLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Lutz AdamLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Marlena StadtmüllerRobert Koch Institut, FG 17 Influenzaviren und weitere Viren des Respirationstraktes, Berlin, Germany.
Sandra SaengerRobert Koch Institut, FG 17 Influenzaviren und weitere Viren des Respirationstraktes, Berlin, Germany.
Stephanie ZimmlerRobert Koch Institut, FG 17 Influenzaviren und weitere Viren des Respirationstraktes, Berlin, Germany.
Katja HönzkeMedizinische Klinik mit Schwerpunkt Infektiologie und Pneumologie, Charité, Universitätsmedizin Berlin, Partner von Freie Universität Berlin, Humboldt-Universität zu Berlin und Berlin Institute of Health, Berlin, Germany.
Ling YaoMedizinische Klinik mit Schwerpunkt Infektiologie und Pneumologie, Charité, Universitätsmedizin Berlin, Partner von Freie Universität Berlin, Humboldt-Universität zu Berlin und Berlin Institute of Health, Berlin, Germany.
Ute HoffmannExperimentelle Rheumatologie, Deutsches Rheuma-Forschungszentrum Berlin, ein Leibniz-Institut, Berlin, Germany.
Markus BarduaExperimentelle Rheumatologie, Deutsches Rheuma-Forschungszentrum Berlin, ein Leibniz-Institut, Berlin, Germany.
Alf HamannExperimentelle Rheumatologie, Deutsches Rheuma-Forschungszentrum Berlin, ein Leibniz-Institut, Berlin, Germany.
Martin WitzenrathMedizinische Klinik mit Schwerpunkt Infektiologie und Pneumologie, Charité, Universitätsmedizin Berlin, Partner von Freie Universität Berlin, Humboldt-Universität zu Berlin und Berlin Institute of Health, Berlin, Germany.
Leif E SanderMedizinische Klinik mit Schwerpunkt Infektiologie und Pneumologie, Charité, Universitätsmedizin Berlin, Partner von Freie Universität Berlin, Humboldt-Universität zu Berlin und Berlin Institute of Health, Berlin, Germany.
Thorsten WolffRobert Koch Institut, FG 17 Influenzaviren und weitere Viren des Respirationstraktes, Berlin, Germany.ORCID http://orcid.org/0000-0001-7688-236X
Andreas C HockeMedizinische Klinik mit Schwerpunkt Infektiologie und Pneumologie, Charité, Universitätsmedizin Berlin, Partner von Freie Universität Berlin, Humboldt-Universität zu Berlin und Berlin Institute of Health, Berlin, Germany.
Stefan HippenstielMedizinische Klinik mit Schwerpunkt Infektiologie und Pneumologie, Charité, Universitätsmedizin Berlin, Partner von Freie Universität Berlin, Humboldt-Universität zu Berlin und Berlin Institute of Health, Berlin, Germany.
Sacha De CarloThermo Fisher Scientific, Eindhoven, The Netherlands.
Jens NeudeckerChirurgische Klinik, Campus Mitte/Campus Virchow Klinikum, Charité, Universitätsmedizin Berlin, Partner von Freie Universität Berlin, Humboldt-Universität zu Berlin, und Berlin Institute of Health, Berlin, Germany.
Klaus OsterriederInstitut für Virologie, Robert von Ostertag-Haus, Zentrum für Infektionsmedizin, Freie Universität Berlin, Berlin, Germany.
Nediljko BudisaInstitut für Chemie, Biokatalyse, Technische Universität Berlin, Berlin, Germany.
Roland R NetzFachbereich Physik, Theoretische Biophysik und Physik weicher Materie, Freie Universität Berlin, Berlin, Germany.
Christoph BöttcherForschungszentrum für Elektronenmikroskopie und Gerätezentrum BioSupraMol, Institut für Chemie und Biochemie, Freie Universität Berlin, Berlin, Germany.
Susanne LieseFachbereich Physik, Theoretische Biophysik und Physik weicher Materie, Freie Universität Berlin, Berlin, Germany. susanlie@math.uio.no.ORCID http://orcid.org/0000-0001-7420-5488
Andreas HerrmannInstitut für Biologie, Molekulare Biophysik, IRI Life Sciences, Humboldt-Universität zu Berlin, Berlin, Germany. andreas.herrmann@rz.hu-berlin.de.ORCID http://orcid.org/0000-0002-6716-2026
Christian P R HackenbergerLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany. hackenbe@fmp-berlin.de.ORCID http://orcid.org/0000-0001-7457-4742
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multivalent interactions at biological interfaces occur frequently in nature and mediate recognition and interactions in essential physiological processes such as cell-to-cell adhesion. Multivalency is also a key principle that allows tight binding between pathogens and host cells during the initial stages of infection. One promising approach to prevent infection is the design of synthetic or semisynthetic multivalent binders that interfere with pathogen adhesion
Indexed as
Virus InternalizationA549 CellsAllolevivirusAnimalsBinding SitesCapsidDogsHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza A virusInfluenza, HumanLigandsMadin Darby Canine Kidney CellsModels, MolecularNanoparticlesOrthomyxoviridae InfectionsHemagglutinin Glycoproteins, Influenza Virushemagglutinin, human influenza A virusLigands
Identifiers
PMID
32231271What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.